I-123 iomazenil SPECT in patients with mental disorders.
The purpose of this study is visual evaluation of the distribution of I-123 iomazenil in the brains of patients with various types of mental disorder and to examine whether chronic administration of a clinical dose of benzodiazepine (BZ) affects the binding of I-123 iomazenil to BZ receptors (BZR). The subjects were 10 patients with mental disorders (3 males and 7 females) with a mean age of 26.8 yrs (range 19-39 yrs). Four of 10 patients were administered BZ for over 3 months and the other six were free of BZ for over one month. The SPECT images were obtained at 5-25 min (early) and 170-190 min (delayed), after the bolus i.v. injection of 167 MBq of I-123 iomazenil, with a triple-head gamma camera. The images were visually evaluated and the washout ratios of each region were calculated. In visual analysis, abnormalities were recognized in 5 patients on the delaye SPECT. The abnormalities were recognized more frequently in the superior frontal lobe. The washout ratio was higher in the BZ (+) patient group than in the BZ (-) patient group. I-123 iomazenil is useful, because the SPECT image with I-123 iomazenil reflects the distribution of BZR on the brain and provides the different information from that obtained with perfusion SPECT, X-ray CT or MRI. The rapid washout of I-123 iomazenil from the brains of BZ (+) patients suggests that chronic administration of a clinical dose of BZ affects the binding of I-123 iomazenil to BZR.
Nakabeppu
Y
Y
Department of Radiology, Faculty of Medicine, Kagoshima University, Japan.
Nakajo
M
M
Naruo
T
T
Obo
Y
Y
Nozoe
S
S
Takigawa
M
M
Tsuchimochi
S
S
Tani
A
A
Tanaka
H
H
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D005442:Flumazenil / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D008297:Male; D001523:Mental Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
D014151:Anti-Anxiety Agents; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D005442:Flumazenil; C063038:iomazenil